Library · Oncology, infection & imaging · Prostate cancer PET imaging
Gallium-68 PSMA-11
68Ga-PSMA-11
First molecular-targeted PET imaging drug for PSMA-positive prostate cancer lesions, FDA-approved December 2020. Used in patients with suspected metastasis being considered for surgery or radiation, or suspected recurrence based on rising PSA.
Research score 90/100. Reference only, not a dose.
- Diagnostic Imaging
- US status
- Prescription Only - Diagnostic
- Approval
- FDA Approved (2020)
- Evidence
- 91% confirmation rate of prostate cancer in patients with positive PET readings (960-patient trials)
- Research score
- 90 / 100
- Indication
- PET imaging of PSMA-positive prostate cancer lesions
- Origin
- United States
- Source category
- Diagnostic & Imaging
- Status group
- Approved / prescription
Mechanism
Binds PSMA on prostate cancer cells; its gallium-68 label emits positrons for PET visualization of PSMA-positive lesions.
Safety file
Well tolerated, with minimal adverse effects.
- Minimal - typical for radiopharmaceutical imaging agents